ArticleFrontiers in neurology2025
Clinical effect of non-convulsive electroconvulsive therapy combined with olanzapine in patients with schizophrenia.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinical effect of non-convulsive electroconvulsive therapy combined with olanzapine in schizophrenia patients. Methods: From September 2021 to August 2023, a total of 112 patients with schizophrenia treated in our hospital were selected as the study participants. These patients were randomly divided into a control group and a research group, with 56 cases in each group. Patients in the control group were administered olanzapine tablets. Based on olanzapine tablets, patients in the research group received non-convulsive electroconvulsive therapy. The psychotic symptoms, severity of schizophrenia symptoms, memory ability, cognitive function, serum BDNF, S100B, and GFAP levels, and incidence of adverse reactions between the two groups were compared. Results: Compared to the control group, the research group had lower BPRS score, lower PANSS score, higher WMS-IV score, higher BACS score, higher serum BDNF level, lower serum S100B and GFAP levels ( Conclusion: Non-convulsive electroconvulsive therapy combined with olanzapine has a significant effect in the treatment of schizophrenia. It can effectively improve mental symptoms and cognitive function of patients, regulate the levels of serum BDNF and S100B, and has high safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.